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Abstract
Imaging in clinical oncology trials provides a wealth of information that contributes to the drug devel-
opment process, especially in early phase studies. This paper focuses on kinetic modeling in DCE-MRI,
inspired by mixed-effects models that are frequently used in the analysis of clinical trials. Instead of
summarizing each scanning session as a single kinetic parameter – such as median Ktrans across all voxels
in the tumor ROI – we propose to analyze all voxel time courses from all scans and across all subjects
simultaneously in a single model. The kinetic parameters from the usual non-linear regression model are
decomposed into unique components associated with factors from the longitudinal study; e.g., treatment,
patient and voxel effects. A Bayesian hierarchical model provides the framework in order to construct a
data model, a parameter model, as well as prior distributions. The posterior distribution of the kinetic
parameters is estimated using Markov chain Monte Carlo (MCMC) methods. Hypothesis testing at the
study level for an overall treatment effect is straightforward and the patient- and voxel-level parame-
ters capture random effects that provide additional information at various levels of resolution to allow a
thorough evaluation of the clinical trial. The proposed method is validated with a breast cancer study,
where the subjects were imaged before and after two cycles of chemotherapy, demonstrating the clinical
potential of this method to longitudinal oncology studies.
2
1 Introduction
Assessing the efficacy of cancer treatments using in vivo imaging is shifting from qualitative techniques
to quantitative imaging methods that characterize biologically relevant properties of tumor tissue. The
use of model-free or heuristic measures, such as the initial area under the Gadolinium curve (IAUGC), or
fully quantitative measures, such as the kinetic parameters from a compartmental model, are relatively
well understood in the analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
(1; 2; 3). Analysis of an oncology imaging trial is usually achieved by applying statistical summaries, such
as the mean or median, to the parameters of interest derived from tissue regions of interest (ROIs). That
is, enhancing (tumor) voxels are identified from the DCE-MRI data for each scan across all subjects and
those voxels are represented by a single parameter; e.g., Ktrans from quantitative analysis and IAUGC90
from a heuristic analysis. Hypothesis testing, either parametric or non-parametric, may then be applied
to the derived statistics in order to assess the effects of treatment.
Applying statistical summaries to the kinetic parameter maps from DCE-MRI however discards a
substantial amount of information contained in the contrast agent concentration time curves (CTCs) at
each voxel, essentially abstracting thousands of observations in space and time to a single number per
scan per subject. We believe that there is a wealth of potential information by retaining the collection
of CTCs across all subjects and scans, acknowledging the fact that not all CTCs are the same and not
all patients are the same.
This paper proposes a Bayesian hierarchical model to analyze all tumor CTCs across all patients and
scans in a given study simultaneously based on the concept of a mixed-effects model. Mixed-effects models
are well established in the statistical community and have found widespread applications in, for example,
agriculture, economics, geophysics and the analysis of clinical trials (4; 5). Mixed-effects models extend
the concept of traditional linear or non-linear models by combining both fixed effects and random effects
in the same model. More generally, mixed-effects models are most often used to describe relationships
between the measured response and explanatory variables in data that are grouped according to one or
more factors. Fixed effects denote parameters that are associated with an entire population and random
effects denote parameters which are associated with random samples from a population. For example, the
drug or radiation therapy given in a trial is a fixed effect because there is no randomness associated with
it, whereas patients are inherently random because they are sampled from the population of all patients
with a given disease. By acknowledging the fact that some parameters are associated with random
samples from a population, we are able to generalize the results from a mixed-effects model beyond the
collection of subjects used in the model fitting.
Bayesian methods are used in the construction and estimation of the generalized additive model (6; 7)
associated with each kinetic parameter in the model of the CTCs. Similarly to mixed-effects models in a
maximum likelihood setting the variances associated with the fixed effects are chosen to be constant, but
the variance terms associated with the random effects have prior distributions. This leads to a shrinkage
estimation of the random effects so that the random effects are pushed towards zero (8). The fixed effect
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in the model explain as much variance as possible, whereas the random effects capture variability that
cannot be explained by the fixed effects.
Formulation of a Bayesian hierarchical model is typically achieved in three stages: the data model,
the parameter model and the prior parameters (9; 10). The data model reflects our knowledge of the
CTCs at the voxel level using the class of compartmental models (11; 12; 13) with a standard arterial
input function (AIF) taken from the literature (14; 15; 16). The process model describes how model
parameters are generated from underlying processes. At this step we decompose the kinetic parameters
into treatment, patient and voxel effects. In Bayesian theory all parameters are regarded as random
variables with pre-specified (prior) distributions. This includes the parameters for the fixed as well as
the random effects in the model. Conjugate distributions with appropriately selected values are used
as priors on all parameters in the model in order to limit their range during the estimation procedure.
These choices also allow us to implement efficient sampling methods, wherever possible, to reduce the
computational burden.
As an illustration of the parameter model let ψ be a kinetic parameter of interest and suppose
the imaging study acquires a dynamic MRI measurement sequence at two time points for each subject –
before and after treatment. The generalized additive model uses the natural logarithm as the link function
between the signal and effects that can be identified from the study design. For example, assume the
imaging study included two time points (pre- and post-treatment) so the parameter ψ may be decomposed
via
lnψ = baseline + treatment + patient + (patient · treatment) + voxel. [1 ]
With model fitting considering all effects related to the kinetic parameter ψ, a curve that fits the observed
data at a particular voxel (associated with a specific scanning session and patient) can be derived. This
is illustrated in Figure 2 where pre- and post-treatment voxels have been selected from three subjects.
The solid line in each plot is the fitted curve to the CTC at a single voxel including all effects in the
model (Eq. [1]).
One can construct different versions of ψ that involve a subset of terms in Eq. [1]. For example, defining
ψˆb = exp(baseline) produces the estimated baseline value of the kinetic parameter across the entire study,
while ignoring patient- and voxel-specific information and ψˆt = exp(baseline + treatment) produces the
estimated treatment value of the kinetic parameter across the entire study when patient- and voxel-specific
information are ignored. In Figure 2, the dotted line in each plot is the fitted curve corresponding to the
posterior median CTC for the whole study pre-treatment (top row) and post-treatment (bottom row).
Relative changes between baseline and treatment are also available by looking at the individual com-
ponents in Eq. [1]; e.g., ψˆt∗ = exp(treatment) produces the percentage change due to treatment relative
to the baseline value ψˆb. Given the mathematical properties of exponential functions, we know that
ψˆb · ψˆt∗ = ψˆt, thus relating the relative changes attributed to specific effects in the generalized additive
model to absolute values of the kinetic parameter. Similar manipulations may be performed to investi-
gate patient- or voxel-specific effects and their relative changes from baseline. This figure is described in
greater detail in the results section.
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The goal of model construction and estimation presented here is to quantify the effect of drug treat-
ment on disease – in this case breast cancer – through quantitative summaries of tumor microvasculature
using DCE-MRI. The model framework we have adopted provides a unified treatment of imaging in-
formation at the study level through simultaneous estimation of parameters at the voxel, patient and
treatment level, allowing a thorough interrogation of the results.
2 Bayesian Hierarchical Model
Bayesian methods rely on the specification of prior distributions p(θ) that express our information about
the unknown parameters θ before any measurements are obtained; i.e., our model assumptions. To assess
the model parameters after observing the data, the posterior distribution p(θ |Y) can be computed, where
θ is the vector of all unknown parameters and Y is the vector of observations. The posterior distribution
of the parameter vector θ is obtained by applying Bayes’ theorem
p(θ |Y) =
p(θ) ℓ(Y | θ)∫
p(θ∗) ℓ(Y | θ∗) dθ∗
, [2 ]
where ℓ(Y | θ) denotes the likelihood function of Y and p(θ) the product of all a priori probability
distribution functions. One can think of the posterior as an update to the prior distribution, our beliefs,
on θ after measuring a process – producing a mixture of previous knowledge and experimental data.
Bayesian methods are inherently iterative, since the posterior distribution can become our new prior
distribution and, be combined with new measurements of the data generating process at a later date, to
produce an updated posterior distribution.
The following sections introduce the key components in the Bayesian hierarchical model: the data
model, the parameter model and the prior parameters. Each stage of the model development has been
tailored to the analysis of a longitudinal cancer treatment study with two time points. Figure 1 provides a
schematic overview of the proposed Bayesian Hierarchical Model (BHM). The three model stages are the
rows and the columns represent the “resolution” of the parameters. For example, Ktrans is decomposed
into global (study-wide), subject and voxel effects through the BHM where as vp is simply estimated for
each voxel without further decomposition. The measurement error term is independent of the specific
parameter model and involves both prior and hyperprior distributions. A standard compartmental model
is used to describe the concentration time curves observed at each voxel. A generalized additive model
is proposed to decompose the kinetic parameters into factors that are relevant to the design of the
longitudinal study. Finally, the prior distributions, including necessary hyperparameters, are specified on
all factors of the parameter model. These prior distributions are flat in most cases, reflecting a lack of
knowledge concerning the parameter, but also incorporate biological knowledge, such as a transfer rate
must be non-negative, or statistical knowledge, for example a variance must be non-negative.
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2.1 Data Model
A hierarchical Bayesian framework is used to model the contrast agent concentration time curve (CTC)
of all voxels (17). Let Y = [Y (t1), Y (t2), . . . , Y (tT )]
T denote the CTC associated with a single voxel
observed at T time points determined by the image acquisition protocol. The CTC is assumed to follow
a standard compartment model (16)
Ct(t) = vpCp(t) + Cp(t)⊗K
trans exp(−t kep), [3 ]
where ⊗ denotes the convolution operator,Ktrans represents the transfer rate from plasma to extracellular
extravascular space (EES) per minute, kep the rate constant between EES and blood plasma per minute
and vp the vascular space fraction. The choice of model for the CTC depends on the scientific goals of the
study. Replacing Eq. [3] with a more or less complicated model is straightforward in this model-building
framework. The observed vector Y may therefore be thought of as noisy observations of the true contrast
agent concentration Ct(t) given by a draw from a multivariate Normal distribution
Y ∼ NT
(
Ct, σ
2IT
)
, [4 ]
where the notation Y ∼ N(µ, σ2) means that the random variable Y is drawn from the Normal distribution
with parameters µ and σ2.
We assume a common arterial input function (AIF), taken from the literature for all patients in the
study, and we follow the work of Tofts and Kermode (12) by using a bi-exponential function
Cp(t) = D[a1 exp(m1t) + a2 exp(m2t)], [5 ]
where a1 = 24.0 kg/l, a2 = 6.20 kg/l, m1 = 3.00 min
−1 and m2 = 0.016 min
−1 are inspired by the work
of Fritz-Hansen et al. (15).
A Bayesian implementation of the compartmental model above was proposed in Schmid et al. (18).
Since the Bayesian model framework does not depend on any optimization procedure, it will produce
valid parameter estimates when estimation via nonlinear regression fails to converge. Samples from the
posterior distribution are built up during the model fitting procedure for each parameter. Hence, the
posterior distribution may be used to obtain additional information on the accuracy and precision of the
estimates. For example, the standard error of the posterior is the estimation error. Statistics of interest
may be derived from the posterior distribution (e.g., mean, median, quantiles, etc. ) so that not only
point estimates but also confidence intervals are readily available.
2.2 Parameter Model
The pharmacokinetic (PK) parameters from the data model are estimated at every tumor voxel across
all subjects and scans. We assume a priori that the distribution of the random variables Ktrans and kep
in the tumor are patient-specific and are changed by treatment in a similar way. Therefore a generalized
additive model is used where the log-transformed kinetic parameters ln(Ktrans) and ln(kep) are expressed
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as a linear combination of fixed- and random-effects associated with identifiable factors in the study.
In addition to mathematical convenience, the log transform is also appealing in this context because
individual terms in the additive model may be interpreted as percentage change from baseline. We
assume that the distribution of the vascular fraction vp will not be changed by the treatment, however
single vp values will be changed. Let i = 1, . . . , I denote the scans acquired and let j = 1, . . . , J denote
the patients, so that nij denotes the number of tumor voxels for patient j at scan i, measured at T
time points. The transfer rate constants in Eq. [3] are assumed to be non-negative and estimated in
log-transformed space. That is, let ψ1 = ln(K
trans), ψ2 = ln(kep) and ψ = [ln(K
trans), ln(kep)]
T.
The factor of interest when measuring a change in the kinetic parameters is the treatment effect, or
the difference between scan i = 1 and scan i = 2 when only pre- and post-treatment images are acquired.
We acknowledge the fact that substantial variability exists across patients in the study and between the
voxels in each region of interest (ROI) that describes the enhancing region in the acquisition. Hence, the
model for ln(Ktrans) is given by
ψijk1 = [1 xi]
 α1
β1
+ [1 xi]
 γj1
δj1
+ ǫijk1, for all i, j, k [6 ]
where
xi =
 1 scan i = 2;0 otherwise. [7 ]
The parameter α1 is the value of ln(K
trans) associated with the baseline scan and β1 is the treatment
effect (since it is only associated with the post-treatment acquisition). These parameters are regarded
as fixed effects (the global column of Figure 1), and thus do not vary between patients in the study.
In the Bayesian framework, a marginal posterior distribution will be available for each parameter. The
parameter γj1 is the effect of patient j on ln(K
trans) and δj1 is the interaction between patient j and
treatment. These parameters are random effects since each patient is assumed to be drawn from a
larger population of patients suffering from this condition (the subject column of Figure 1). Finally, the
parameter ǫijk1 is the random effect of voxel k in scan i of patient j on ln(K
trans). The voxel effect
acknowledges the fact that each voxel in the tumor volume is drawn from a distribution that describes
the ideal tumor voxel (the voxel column of Figure 1). The combination of fixed and random effects in a
single model is commonly referred to as a mixed-effects model (6).
Using matrix notation, we can combine the generalized additive model across both kinetic parameters,
lnKtrans and ln kep, such that
ψijkl = Zi
 φ
θj
+ ǫijkl [8 ]
Xi =
 1 xi 0 0
0 0 1 xi
 ; Zi = [Xi Xi]; φl =

α1
β1
α2
β2
 ; θjl =

γj1
δj1
γj2
δj2
 ; ǫijkl =
 ǫijk1
ǫijk2
 [9 ]
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The scan-specific covariates in the model are captured in Zi, the fixed effects are in φl, the patient-specific
random effects are in θjl and the voxel-specific random effects are in ǫijkl . The model formulation in
Eq. [8] can be adapted in order to incorporate a greater number of scans in a longitudinal study.
2.3 Prior Models
In the Bayesian framework prior information with unknown variance is used to model the random effects.
We use vector notation to denote the patient-specific random effects such that
γ =

γ11
γ21
...
γJ1
γ12
...
γJ2

and δ =

δ11
δ21
...
δJ1
δ12
...
δJ2

, [10]
where we have dropped the kinetic parameter subscript to simplify the notation. We draw from mul-
tivariate Gaussian distributions to characterize the prior distribution of the unknown variances for the
patient-specific random effects, i.e.,
γ ∼ N2J
(
0, diag
(
τ 2γ
))
, [11]
δ ∼ N2J
(
0, diag
(
τ 2δ
))
, [12]
where τ 2γ and τ
2
δ are vectors of the same length and indexed as γ and δ, respectively. The voxel-specific
random-effect vectors are given unique prior distributions by scan, patient and parameter, so that each
vector is given by ǫijl = [ǫij1l, ǫij2l, · · · , ǫijnij l]
T and it is drawn from a multivariate Gaussian distribution
via
ǫijl ∼ Nnij
(
0, τ2ǫ;ijlInij
)
[13]
where nij is the number of voxels in the region of interest of scan i of patient j, and τ
2
ǫ;ijl is the unknown
variance associated with scan i, patient j and parameter l. Since the variances are unknown parameters,
they must have their own prior distributions which are given by
τ 2γ
iid
∼ IG(1, 1) , [14]
τ 2δ
iid
∼ IG(1, 1) , [15]
τ 2ǫ
iid
∼ IG
(
1, 10−5
)
, [16]
where IG(a, b) denotes the Inverse Gamma distribution (19), allowing only non-negative values. The
inverse Gamma distribution is a conjugate prior for the Normal distribution. For the fixed effects we use
flat priors; i.e., the prior distribution does not contain any relevant information, such that
p(αl) = p(βl) = constant for l = 1, 2. [17]
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The prior distributions on the coefficients in the generalized additive model are chosen so that as much
variance in the data is explained by the fixed effects α and β – as no prior information is used for those
parameters. Variability which cannot be explained by the fixed effects will be covered by the random
effects γ and δ. For these parameters an additional prior distribution (hyperprior) on the variance of
the parameters is defined, which leads to a shrinkage of those effects, that is the parameters are pushed
towards zero and therefore do not cover variance explained by the fixed effects. Any additional variance
is explained by the voxel effects.
For the vascular space fraction we impose a relatively flat prior
vp;ijk
iid
∼ B(1, 19), for all i, j, k, [18]
where B(a, b) denotes the Beta distribution (20), so that the a priori expected value of vp is 0.05.
The Bayesian hierarchical model is complete by specifying a prior distribution for the variance of the
observational error in Eq. [4], with one variance parameter per scan per patient,
σ2ij
iid
∼ IG(1, 10−2) for all i, j. [19]
3 Materials and Methods
3.1 Data acquisition
The first twelve patients from a previously reported breast cancer study are included in the analysis
(21; 18). Data were provided by the Paul Strickland Scanner Centre (PSSC) at Mount Vernon Hospital,
Northwood, UK. Each patient underwent a DCE-MRI study before and after two cycles of chemotherapy
(5-fluorouracil, epirubicin and cyclophosphamide). Six of these patients were identified as pathological
responders after receiving six cycles of chemotherapy, the others were non-responders.
For the calculation of T1 values, we used a two-point measurement with calibration curves as described
in (22; 23). The T1 values are computed as ratio of a T1-weighted fast low-angle shot (FLASH) image and
a proton density weighted (PDw) FLASH image. The imaging parameters of the T1-weighted FLASH
images were TR = 11 ms, TE = 4.7 ms, α = 35◦, the parameters of the proton density-weighted image
were TR = 350 ms, TE = 4.7 ms, α = 6◦. Field of view was the same for all scans, 260 × 260 × 8 mm
per slice, so voxel dimensions were 1.016 × 1.016 × 8 mm. A scan consists of three sequential slices of
256 × 256 voxels and one slice placed in the contra lateral breast as control, which we do not use for
our analysis. A total of 40 to 50 acquisitions were acquired, with one acquisition each 11.9 seconds. A
dose of D = 0.1 mmol per kg body weight of Gd-DTPA was injected after the fourth scan using a power
injector with 4 ml/s with a 20 ml saline flush also at 4 ml/s. The first four scans, before contrast, were
used to compute T10 as the average of the T1 values of these images. Data from this study were acquired
in accordance with the recommendation given by (24). Informed consent was obtained from all patients.
Regions of interest (ROIs) were drawn manually by an expert radiologist on a scan-by-scan basis using
anatomical images and subtraction images from the dynamic data to define tumor voxels in pre and post
treatment scans.
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3.2 Parameter Estimation via MCMC
The joint posterior distribution of all parameters was assessed using Markov chain Monte Carlo (MCMC)
(25). After a initial burn-in phase of 10,000 iterations, another 100,000 iterations were computed. To
ensure independent samples only each 100th sample was used, giving us a total of 1000 samples to
describe the posterior distribution. The global parameters φ and patient-specific θj were drawn en bloc
in Gaussian Gibbs steps (26), and hyperparameters were drawn in independent Gamma Gibbs steps;
technical details can be found in Appendix A.1. Metropolis-Hastings steps with random walk proposals
were necessary for the voxel-specific random effects and vascular space fraction. The algorithm was
tuned to an acceptance rate of 30-50% (27). Summary statistics were computed from the samples of
the posterior distribution to provide point estimates of the parameters. Empirical standard errors, along
with sample quantiles, were used to characterize the precision of the parameter estimates.
4 Results
All parameter estimates are derived from the posterior distribution using Bayes theorem. Hence, a
sampling distribution for each parameter value has been built up from which we can produce a point
estimate via the median of the sample and also credible intervals (Bayesian confidence intervals) by using
the quantiles from their sampling distributions.
How the individual parameters from the generalized additive model coalesce to fit the observed con-
trast agent concentration time curve is illustrated, at the voxel level, in Figure 2. The observed CTCs
for two voxels from three subjects, one voxel at baseline and one voxel after treatment, are plotted along
with three fitted curves. The best estimate from the Bayesian hierarchical model at a specific voxel is
provided by the solid lines in each plot. That is, all parameters from the generalized additive model
(Eq. [8]) are used in the parameter model in order to fit the data model. These curves are very similar
to, but not exactly the same as, model fits from the standard non-linear regression method used in the
quantitative analysis of DCE-MRI data (18). Removing the voxel-specific term from the model produces
a fitted curve that is associated with patient and treatment effects, but not the specific voxel, and are
plotted as dashed lines in Figure 2. Given the presence of inter-voxel heterogeneity in the tumor ROI,
the dashed lines may or may not fit the observed data at a given voxel very well but they do represent
the best (in the sense of a posterior median) fit to all voxels in the tumor ROI for a given patient at a
single scan time point. Going back one more level in the generalized additive model and removing the
patient effect leaves a fitted curve associated with the baseline and post-treatment scans (i.e., two curves
that summarize the overall treatment effect) given by the dotted lines. The top row of Figure 2 contains
voxels from three subjects before treatment so the dotted lines are identical and represent the best (in the
sense of a posterior median) fit to all pre-treatment voxels across all subjects. The bottom row contains
voxels from the same subjects after treatment and the dotted line is the best fit to all post-treatment
voxels.
Figure 3 shows the posterior distributions of pre-treatment (baseline) Ktrans and post-treatment
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Ktrans. That is, the posterior samples were transformed via exp(α1) and exp(α1 + β1), respectively. For
ease of comparison between the two posterior distributions a smoothed version of each histogram, known
as a kernel density estimate, is displayed (28). The posterior median ofKtrans at baseline is 0.205, and the
posterior median of Ktrans after treatment is 0.156. Credible intervals for Ktrans, that cover 95% of the
posterior distribution, are [0.186, 0.234] at baseline and [0.121, 0.198] after treatment. A credible interval
is a posterior probability interval. That is, the true value of Ktrans lies in the interval [0.186, 0.234] with
posterior probability 0.95 at baseline and in [0.121, 0.198] with posterior probability 0.95 after treatment.
The density estimates in Figure 3 are unimodal and indicate an overall decrease in Ktrans after
treatment. In order to test for a treatment effect on Ktrans, specifically a reduction in Ktrans in the
second acquisition compared to the first, we construct the hypothesis
H0 : β1 > 0 versus H1 : β1 ≤ 0, [20]
using the treatment effect from the parameter model (Eq. [8]) and calculate the posterior probability of
β1 exceeding zero. From the results of the MCMC simulation, the null hypothesis (Eq. [20]) is rejected
with p = 0.001.
When introducing the generalized additive model previously the fact that the parameterKtrans and the
covariates are linked through a logarithmic transform leads to the interpretation of individual covariates in
the parameter model as percentage changes from baseline instead of absolute changes. For the treatment
effect this translates into a 100% · |0.7659− 1| = 23.3% median reduction in Ktrans from baseline, where
the sign determines whether the change is associated with an increase or decrease.
Figure 4 shows the patient-specific posterior distributions for pre-treatment Ktrans, given by exp(α1+
γj1) for j = 1, . . . , 12, and post-treatment K
trans, given by exp(α1+β1+γj1+ δj1) for j = 1, . . . , 12. The
clinical responders are grouped in the first two columns of Figure 4 and the clinical non-responders are
in the third and fourth columns. The same range for x-axis [0, 0.45] was used in all plots of Ktrans for
comparison. In general the decrease inKtrans observed in the clinical responders is greater than the clinical
non-responders, but this is not absolute. For example, patient 12 shows only a small decrease in Ktrans
post-treatment and patient 6 shows an increase in Ktrans after treatment, but both are clinical responders
after additional chemotherapy. The interpretation of the treatment effect as a percentage change from
baseline helps to quantify the results in Figure 4. The median percentage change in Ktrans for subject j
is obtained via 100% · | exp(βˆ1 + δˆj1) − 1|, where the sign determines whether an increase or decrease
occurred. For example, patient 1 (pathological responder) experienced a 100% · |0.7684 − 1| = 23.2%
median reduction in Ktrans which is very similar to the overall treatment effect. This is definitely not the
norm as patient 9 experienced a 100% · |0.4285 − 1| = 57.2% median reduction in Ktrans and patient 6
experienced a 100% · |1.0817− 1| = 8.17% median increase in Ktrans, both were pathological responders.
Figure 5 shows the voxel-specific median posterior for pre- and post-treatment Ktrans. The clinical
responders are grouped in the first two columns and the clinical non-responders are in the third and
fourth columns (identical to Fig. 4). The range for the x-axis was restricted to [0, 1] in all plots for
comparison. Given the number of samples from the posterior distribution across all voxels, the median
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value of exp(α1 + γj1 + ǫ1jk1) for j = 1, . . . , 12; k = 1, . . . , n1j and exp(α1 + β1 + γj1 + δj1 + ǫ2jk1) for
j = 1, . . . , 12; k = 1, . . . , n2j across the 1000 samples, for each voxel k, was computed to summarize the
voxel effect. The resulting histograms for the voxel effect have been summarized by a kernel density
estimate. Most voxel-level distributions of median Ktrans show a substantial change in shape after
treatment, although this is more apparent in the responders compared to the non-responders. It is
interesting to note the extent of changes in the shape of these distributions between the different subjects.
For example, patient 11 is characterized by a tumor with two distinct modes in estimated Ktrans at
baseline and a single mode after treatment. Even more interesting is the fact that the post-treatment
distribution of Ktrans is in between the two modes at baseline. The distributions of median Ktrans for
patient 12 show the reverse effect, albeit much more subtle than patient 11, where the post-treatment
distribution of median Ktrans appears to be bimodal but still spans a similar range of values.
5 Discussions and conclusions
Information is obtained at multiple levels during an imaging study in the clinical trial setting. The
main scientific question of interest is usually, was there a treatment effect? This key hypothesis test
drives study design by influencing critical experimental design parameters such as power and sample
size. However, information at other levels, such as the patient or voxel level, can provide insight into
much more subtle features concerning patients, tumors and the treatment effect. Patient variability with
application to predicting clinical response and tumor heterogeneity, as measured by voxel-wise properties
of the pharmacokinetic model, are just two examples of so-called secondary endpoints.
The Bayesian hierarchical model presented here was developed to test the hypothesis of a treatment
effect for an imaging study while acknowledging known sources of uncertainty; e.g., patients and voxels.
This is similar to the approach taken in standard analysis methods for clinical trials where fixed and
random effects are identified in the model. The specification of fixed and random effects allows the
results from the study to be applicable beyond the specific patient population recruited for this specific
study.
A standard analysis was performed on the ROIs and the median Ktrans values have been summarized
in Table 1. A non-parametric test (a one-sided Wilcoxon signed rank test) was performed to test that
the difference between the median values was greater than zero; i.e., the treatment did not reduce Ktrans
across all subjects. The null hypothesis was rejected at a borderline significance level (p = 0.055). Given
the small sample size, N1 = 6 responders and N2 = 6 non-responders, this is an impressive result and
there is obviously a reasonable difference in Ktrans between the two groups.
Figure 6 shows the kernel density estimates of Ktrans for each ROI, before and after treatment, using
a voxel-wise non-linear regression analysis. That is, the compartmental model in Eq. [3] was fit to each
voxel independently using the Levenberg-Marquardt optimization procedure. The empirical distributions
observed for each patient are extremely similar to those obtained in the BHM. This is to be expected
given the relatively flat priors that were imposed on the kinetic parameters (18).
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While the voxel-wise results from the Bayesian and regression methods are very similar, and thus
provide a check on the consistency of the Bayesian model fitting procedure, the advantages of the Bayesian
hierarchical model are clear through the coefficients from the generalized additive model (Eq. [8]). The
regression analysis can only summarize the study through Table 1, but the BHM allows one to isolate
and interrogate specific effects, at the study or patient or voxel level, through the generalized additive
model. Examples of such interrogations have been presented here in Figures 3 and 4, but the possibilities
for such model summaries are only limited by the construction of the parameter model.
Bayesian models rely on a priori beliefs about the model and parameters, expressed as prior distribu-
tions. In general, a flat prior provides similar information to a maximum likelihood approach, and hence
similar results. However, in the Bayesian hierarchical model proposed here the choice of prior distribution
is critical in specifying the model. We used flat priors on the baseline α and on the treatment effect β,
and thus the approach is similar to a non-Bayesian or frequentist approach. For the patient specific
effects γ and δ we used Gaussian priors with unknown variances; this is also known as shrinkage prior, as
it shifts the parameters towards zero. Hence the patient-specific effects only pick up the deviation from
baseline and treatment effect. The voxel effect was also given a shrinkage prior with a more informative
hyperprior distribution on the variance, hence it only picks up variability after modelling the baseline,
treatment and patient-specific effects.
In this paper a generalized additive model was constructed for the kinetic parameters (Ktrans and
kep) in a compartmental model. This model incorporated two scanning sessions, and all subjects, to
asses the effect of treatment. The modeling framework is easily extended to handle additional covariates
or scanning sessions. For example, a dose-ranging study design could be incorporated into the additive
model where the treatment effect can be expressed as a function of the dose. Additional scans over time
would enable the assessment of temporal dependence on treatment and provide information about the
reliability of the data by potentially reducing the amount of uncertainty in the parameter estimates.
Another possible extension of this model would be to include the spatial information of adjacent voxels.
In the current implementation of the Bayesian hierarchical model all voxels from one region of interest
(tumor) were treated as spatially independent. Since voxel borders are arbitrary and do not represent
physiological boundaries between different tissue types, it is likely that neighboring voxels share similar
perfusion characteristics. This fact has been taken advantage of in the context of Bayesian modeling of
individual scans from a DCE-MRI study (18). The inclusion of a neighborhood structure in the modeling
process would reduce the uncertainty in estimation and provide more reliable estimates of the kinetic
parameters.
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A Appendix
A.1 Full conditional distributions
In each iteration of the MCMC (Markov chain Monte Carlo) algorithm, a random sample of the marginal
posterior distribution for all parameters is drawn. This is performed by drawing from the conditional
posterior distribution of one or more parameters given all other parameters and the data. Hence, the
full conditional distributions must be computed. The full conditional is denoted by θ | ·, where θ is the
parameter and · denotes all other parameters and the data. If the full conditional takes the from of a
standard distribution, one can sample directly form this distribution; this is known as the Gibbs sampler
(25). If the full conditional is not a standard distribution, then a Metropolis-Hastings sampler must be
constructed.
In the proposed Bayesian hierarchical model all full conditionals are from standard distributions due
to the use of conjugate prior distributions, except for the voxel effect and vp. Let ξl = (αl, βl,γl, δl)
denote the vector of length P = I(J+1) associated with all parameters in the generalized additive model,
except the voxel effect, for a specific kinetic parameter. The full conditional of ξl is a multivariate Normal
distribution given by
ξl | · ∼ NP
(
V
−1
m,V−1
)
,
m = [m1, . . . ,mP ]
T,
mp =
2∑
i=1
J∑
j=1
(
τǫ;ij
nij∑
k=1
wijpψijkl
)
for p = 1, . . . , P ,
V = WTΛW + diag (0, 0, τγ;1l, . . . , τγ;Jl, τδ;1l, . . . , τδ;Jl),
where W is a I(J +1)×P matrix indicating which covariate should be included in the parameter model
(Eq. [8]) and Λ is a diagonal matrix with elements nijτǫ;ij . The vector ξl is drawn in one block from a
multivariate Normal distribution with an efficient block-sampling algorithm (29).
The full conditional distribution of the voxel effect ǫijkl is a non-standard distribution. For computa-
tional reasons it is more convenient to sample from ψijkl rather than from ǫijkl. where the full conditional
distribution of ψijkl is given by
p(ψijkl | ·) ∝ exp
(
−
1
2
τǫ;ijkψ
2
ijkl −
1
2σ2jk
(
Yijkl − Ŷijkl
)2)
. [21]
Note, Ŷijkl is the estimated contrast agent concentration curve given by the estimated model parameters
in ψˆijkl. Draws from this distribution are obtained using a Metropolis-Hastings step.
The full conditionals of all variance parameters are inverse Gamma distributions, which are given by
τ2γ | ·
iid
∼ IG
(
1.5, 1 + γ2jl
)
, [22]
τ2δ | ·
iid
∼ IG
(
1.5, 1 + δ2jl
)
, [23]
τ2ǫ | ·
iid
∼ IG
1 + 12
I∑
i=1
J∑
j=1
nij , 10
−5 +
1
2
I∑
i=1
J∑
j=1
nij∑
k=1
Zi
 φ
θj
− ψijkl
2
 . [24]
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Hence, the variance parameters can be drawn independently.
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Figure Captions
1. Schematic overview of the Bayesian hierarchical model for the observed contrast agent concentration
time curves.
2. Contrast concentration time curves (CTCs) for pre- and post-treatment scans in three different
subjects. Solid lines indicate the voxel-specific fit to the CTC, dashed lines the combined patient-
and treatment-specific CTCs, and dotted lines the global pre- and post-treatment median CTCs
for the entire study.
3. Samples from the marginal posterior distributions of Ktrans at the study level. At pre-treatment
Ktrans is given by exp(α1) and at post-treatment K
trans is given by exp(α1 + β1).
4. Samples from the marginal posterior distributions of Ktrans at the patient level. At pre-treatment
Ktrans is given by exp(α1 + γj1) for patient j and at post-treatment K
trans is given by exp(α1 +
β1 + γj1 + δj1) for patient j.
5. Smoothed histograms summarizing the values of the posterior median Ktrans at the voxel level.
At pre-treatment Ktrans is given by exp(α1 + γj1 + ǫ1jk1) for scan 1, patient j and voxel k. At
post-treatment Ktrans is given by exp(α1 + β1 + γ1j + δ1j + ǫ12jk) for scan 2, patient j and voxel k.
The x-axis has been restricted to [0, 1] for visualization.
6. Smoothed histograms summarizing the values of Ktrans from voxel-wise non-linear regression anal-
ysis. The x-axis has been restricted to [0, 1] for visualization.
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Table 1: Median Ktrans values from the standard analysis (R = responder, NR = non-responder).
Patient ID 1 2 3 4 5 6 7 8 9 10 11 12
pathological R R R NR NR R NR NR R NR NR R
pre 0.208 0.355 0.255 0.230 0.199 0.154 0.264 0.198 0.305 0.267 0.432 0.174
post 0.161 0.120 0.031 0.245 0.208 0.173 0.327 0.223 0.122 0.221 0.111 0.113
vpK
trans, kep
Beta-Prior
Voxel
flat prior
Gaussian with
unknown var.
D
a
ta
 m
o
d
e
l
P
a
ra
m
e
te
r 
m
o
d
e
l
P
ri
o
r 
m
o
d
e
l
global subject voxel-specific
Gaussian with
unknown var.
Gaussian with
unknown var.
Hyperprior
for variance
Hyperprior
for variance
Hyperprior
for variance
Baseline
Treatment
Patient eff.
Interaction
effect
Ct
Observation
ErrorY = +
Figure 1:
19
Time in minutes
Co
nt
ra
st
 c
on
ce
nt
ra
tio
n
0.0
0.1
0.2
0.3
0.4
0.5
0 1 2 3 4 5 6
Post treatment patient 1 Post treatment patient 2
0 1 2 3 4 5 6
Post treatment patient 3
Pre treatment patient 1
0 1 2 3 4 5 6
Pre treatment patient 2
0.0
0.1
0.2
0.3
0.4
0.5
Pre treatment patient 3
Figure 2:
Ktrans
Po
st
er
io
r D
en
si
ty
0
5
10
15
20
25
0.1 0.2 0.3
pre−treatment
post−treatment
Figure 3:
20
Ktrans
Po
st
er
io
r D
en
si
ty
0
200
400
600
800
0.0 0.1 0.2 0.3 0.4
Patient 1 Patient 2
0.0 0.1 0.2 0.3 0.4
Patient 4 Patient 5
Patient 3 Patient 6 Patient 7
0
200
400
600
800
Patient 8
0
200
400
600
800
Patient 9
0.0 0.1 0.2 0.3 0.4
Patient 12 Patient 10
0.0 0.1 0.2 0.3 0.4
Patient 11
pre−treatment
post−treatment
Figure 4:
Ktrans
Po
st
er
io
r D
en
si
ty
0
5
10
15
20
0.0 0.2 0.4 0.6 0.8 1.0
Patient 1 Patient 2
0.0 0.2 0.4 0.6 0.8 1.0
Patient 4 Patient 5
Patient 3 Patient 6 Patient 7
0
5
10
15
20
Patient 8
0
5
10
15
20
Patient 9
0.0 0.2 0.4 0.6 0.8 1.0
Patient 12 Patient 10
0.0 0.2 0.4 0.6 0.8 1.0
Patient 11
pre−treatment
post−treatment
Figure 5:
21
Ktrans
Po
st
er
io
r D
en
si
ty
0
5
10
15
0.0 0.2 0.4 0.6 0.8 1.0
Patient 1 Patient 2
0.0 0.2 0.4 0.6 0.8 1.0
Patient 4 Patient 5
Patient 3 Patient 6 Patient 7
0
5
10
15
Patient 8
0
5
10
15
Patient 9
0.0 0.2 0.4 0.6 0.8 1.0
Patient 12 Patient 10
0.0 0.2 0.4 0.6 0.8 1.0
Patient 11
pre−treatment
post−treatment
Figure 6:
22
